Antimicrobial resistance of <i>Pseudomonas aeruginosa</i>: navigating clinical impacts, current resistance trends, and innovations in breaking therapies

Simple item page
datacite.alternateIdentifier.citationFRONTIERS IN MICROBIOLOGY,Vol.15,2024
datacite.alternateIdentifier.doi10.3389/fmicb.2024.1374466
datacite.creatorElfadadny, Ahmed
datacite.creatorRagab, Rokaia F.
datacite.creatorAlHarbi, Maha
datacite.creatorBadshah, Farhad
datacite.creatorIbanez Arancibia, Eliana
datacite.creatorFarag, Ahmed
datacite.creatorHendawy, Amin Omar
datacite.creatorDe los Rios Escalante, Patricio R.
datacite.creatorAboubakr, Mohamed
datacite.creatorZakai, Shadi A.
datacite.creatorNageeb, Wedad M.
datacite.date2024
datacite.subject.englishPseudomonas aeruginosa
datacite.subject.englishresistance
datacite.subject.englishpathogenicity
datacite.subject.englishvirulence
datacite.subject.englishtherapy
datacite.titleAntimicrobial resistance of <i>Pseudomonas aeruginosa</i>: navigating clinical impacts, current resistance trends, and innovations in breaking therapies
dc.date.accessioned2024-05-27T18:27:20Z
dc.date.available2024-05-27T18:27:20Z
dc.description.abstractPseudomonas aeruginosa, a Gram-negative bacterium, is recognized for its adaptability and opportunistic nature. It poses a substantial challenge in clinical settings due to its complicated antibiotic resistance mechanisms, biofilm formation, and capacity for persistent infections in both animal and human hosts. Recent studies revealed a potential zoonotic transmission of P. aeruginosa between animals, the environment, and human populations which highlights awareness of this microbe. Implementation of the One Health approach, which underscores the connection between human, animal, and environmental health, we aim to offer a comprehensive perspective on the current landscape of P. aeruginosa management. This review presents innovative strategies designed to counteract P. aeruginosa infections. Traditional antibiotics, while effective in many cases, are increasingly compromised by the development of multidrug-resistant strains. Non-antibiotic avenues, such as quorum sensing inhibition, phage therapy, and nanoparticle-based treatments, are emerging as promising alternatives. However, their clinical application encounters obstacles like cost, side effects, and safety concerns. Effectively addressing P. aeruginosa infections necessitates persistent research efforts, advancements in clinical development, and a comprehension of host-pathogen interactions to deal with this resilient pathogen.
dc.identifier.urihttps://repositoriodigital.uct.cl/handle/10925/5747
dc.language.isoen
dc.publisherFRONTIERS MEDIA SA
dc.sourceFRONTIERS IN MICROBIOLOGY
oaire.resourceTypeReview
uct.indizacionSCI
Files
Collections
MigraciĆ³n Web of Science